The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight ...
Amid the growing popularity of drugs used for weight loss like Ozempic, Wegovy, Mounjaro and Zepbound, one question has ...
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a research note.
Designed to celebrate diverse, unique portrayals of individuals who partner with their healthcare professional to change the course of their weight-management journey, while educating on the clinical ...
A new examination of research published last year found that people maintained an average 10% weight loss over four years ...
Structure Therapeutics’ American depositary receipts gained more than 6% premarket on Monday after the company said its ...
Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...
Structure's once-daily oral drug, GSBR-1290, belongs to the same class of treatments as Novo Nordisk's blockbuster weight-loss drug Wegovy and Eli Lilly's Zepbound. Leerink analysts said in a note ...
An experimental GLP-1 pill helped people with obesity lose significantly more weight than a placebo over three months, according to summary results revealed by developer Structure Therapeutics Monday.